The judge rejected Mylan's claim that the 693 patent was invalid based on obviousness, meaning that a person of ordinary skill in the art could have formulated the patent's claims using publicly available information.
May 24, 2023 at 05:34 PM
2 minute read
A Newark, New Jersey, federal judge has halted an effort by Pennsylvania-based Mylan Pharmaceuticals Inc. to produce a generic version of Invega Trinza, a Janssen Pharmaceuticals Inc. drug for the treatment of schizophrenia.
The ruling by U.S. District Judge Evelyn Padin bars Mylan from producing a generic version of Invega Trinza until 2036.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Credit: OlekAdobe/Adobe Stock
